SCHEMBL1009307

SCHEMBL1009307

O=C(O)C(CC1CCCC1)n1ncc(Oc2ccccc2)cc1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.43
METAP2 P50579 1/20 0.39
METAP1 P53582 1/20 0.39
PDE1C Q14123 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
EGLN1 Q9GZT9 1/20 0.37
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
PKM P14618 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
GPR132 Q9UNW8 1/20 0.36
MCHR2 Q969V1 1/20 0.36
MCHR1 Q99705 1/20 0.36
KDM2B Q8NHM5 3/20 0.35
CTSS P25774 2/20 0.35
CTSL P07711 1/20 0.35
BCL2 P10415 1/20 0.35
FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008862 0.97 NPY5R (0.41) NPY5RMETAP2METAP1PDE1CNR1H4
SCHEMBL1009289 0.91 NPY5R (0.44) NPY5RMETAP2METAP1PDE1CNR1H4
SCHEMBL1007742 0.91 GPR132 (0.42) NPY5REGLN1HRH3GPR132FFAR1
SCHEMBL1007921 0.90 NPBWR1 (0.44) NPY5RCTSSCTSLFFAR1
SCHEMBL1008428 0.90 ABL1 (0.38) HRH3BCL2
SCHEMBL1008255 0.90 CTSS (0.39) NPY5RPDE1CHRH3CTSSCTSL
SCHEMBL1008741 0.87 LPAR1 (0.39) METAP2METAP1
SCHEMBL1008265 0.87 FFAR1 (0.40) METAP2METAP1EGLN1FFAR1
SCHEMBL1007288 0.87 LPAR1 (0.41) METAP2METAP1EGLN1HRH3FFAR1
SCHEMBL1007389 0.87 GCK (0.40) NPY5REGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK NPY5R 2254/4885METAP2 1286/4885METAP1 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.